What is ProPhase Labs Interest Expense?
Interest Expense is the amount reported by a company or individual as an expense for borrowed money. ProPhase Labs's interest expense for the
three
months ended in Dec. 2023 was $ -0.49 Mil.
Its interest expense for the trailing twelve months (TTM) ended in Dec. 2023 was $-1.28 Mil.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. ProPhase Labs's Operating Income for the
three
months ended in Dec. 2023 was $ -11.35 Mil. ProPhase Labs's Interest Expense for the
three
months ended in Dec. 2023 was $ -0.49 Mil.
ProPhase Labs did not have earnings to cover the interest expense.
The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
ProPhase Labs Interest Expense Calculation
Interest Expense is the amount reported by a company or individual as an expense for borrowed money.
Interest Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.28 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ProPhase Labs (NAS:PRPH) Interest Expense Explanation
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.
Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
ProPhase Labs's Interest Expense for the
three
months ended in Dec. 2023 was $-0.49 Mil. Its
Operating Income
for the
three
months ended in Dec. 2023 was $-11.35 Mil. And its Long-Term Debt & Capital Lease Obligation for the
three
months ended in Dec. 2023 was $18.59 Mil.
ProPhase Labs's Interest Coverage for the quarter that ended in Dec. 2023 is calculated as
| ProPhase Labs did not have earnings to cover the interest expense. |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The higher the ratio, the stronger the company's financial strength is.
ProPhase Labs (ProPhase Labs) Business Description
Traded in Other Exchanges
N/A
Address
711 Stewart Avenue, Suite 200, Garden City, NY, USA, 11530
ProPhase Labs Inc is a diversified company that offers a range of services including diagnostic testing, genomics testing and contract manufacturing. Its operating segments include Diagnostic services and Consumer products. The Diagnostic services segment provides COVID-19 diagnostic information services to a broad range of customers in the United States, including health plans, third-party payers and government organizations. The Consumer products segment is engaged in the research, development, manufacture, distribution, marketing and sale of OTC consumer healthcare products and dietary supplements in the United States and also provide personal genomics products and services.
Executives
| Morse Robert A. Jr. |
officer: Controller |
711 STEWART AVENUE, SUITE 200, GARDEN CITY NY 11530 |
| Billy Joe White |
officer: Chief Financial Officer |
191 OTTO ST., PORT TOWNSEND WA 98368 |
| Jason Michael Barr |
director |
902 BROADWAY, 15TH FLOOR, NEW YORK NY 10010 |
| Louis Md Gleckel |
10 percent owner |
C/O PROHEALTH CARE ASSOCIATES LLP, 2800 METRUS AVE, LAKE SUCCESS NY 11042 |
| Ted William Karkus |
10 percent owner |
188 HEWLETT NECK ROAD, WOODMERE NY 11598 |
| Warren Hirsch |
director |
621 N. SHADY RETREAT ROAD, DOYLESTOWN PA 18901 |
| Monica L. Brady |
officer: Chief Accounting Officer |
621 N. SHADY RETREAT ROAD, DOYLESTOWN PA 18901 |
| Cuddihy Robert V Jr |
officer: Chief Operating Officer |
PARKER DURYEE ET AL, 529 FIFTH AVE 8TH FL, NEW YORK NY 10017 |
| Braden Michael Leonard |
10 percent owner |
156 S. FIRST STREET, ZIONSVILLE IN 46077 |
| Mark S Leventhal |
10 percent owner |
THE BEACON COMPANIES, 50 FEDERAL STREET, BOSTON MA 02468 |
| Mark Shawn Frank |
director |
104 WHISPER WOOD COURT, WRIGHTSTOWN PA 18940 |
| James T Mccubbin |
director |
|
| Mark A. Burnett |
10 percent owner |
40 HEMLOCK DRIVE, ROSLYN NY 11576 |
| Guy J Quigley |
director, 10 percent owner, officer: Chairman, President, CEO |
C/O THE QUIGLEY CORP KELLS BUILDINGS, 621 SHADY RETREAT RD P O BOX 1349, DOYLESTOWN PA 18901 |
| John Deshazo |
10 percent owner |
17 WOLCOTT COURT, BOSTON MA 02136 |
ProPhase Labs (ProPhase Labs) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
PRPH has been successfully added to your 